#United States #Somerset #Proton Therapy #Prostate Cancer #ProCure Proton

ProCure Proton Therapy Center Calls for Media Collaboration

With an alarming rate of prostate cancer affecting one in every eight men in the United States, the ProCure Proton Therapy Center has taken a proactive stance urging media organizations to help inform the public about proton therapy. This specialized treatment method is often misunderstood, leading to missed opportunities for effective cancer care. Dr. Brian Chon, Medical Director at ProCure, emphasizes the significance of educating both patients and healthcare practitioners about the advantages of this powerful therapy.

In conventional radiation therapy, neighboring healthy tissues may inadvertently absorb harmful rays, potentially leading to various side effects. However, proton therapy aims to target cancer cells with precision while minimizing damage to surrounding healthy tissues. Studies have indicated that proton therapy can reduce unwanted radiation exposure to the bladder and bowels by a striking 60-70% when compared to standard radiation treatments. Dr. Chon reflects on this: “Our team is certain that with adequate media coverage and responsible journalism, we can clarify misconceptions and highlight why proton therapy should be considered more frequently by prostate cancer patients.”

Despite some misconceptions that proton therapy is still in the experimental phase, it has enjoyed FDA approval since 1988. Numerous peer-reviewed research articles, most notably by Smith et al. in the International Journal of Radiation, Oncology, Biology, and Physics, have documented encouraging cancer survival rates, along with a notably lower occurrence of side effects in patients undergoing this form of treatment. These findings underscore the need to reassess the perception of proton therapy in the oncology community.

Adding to the narrative, accessibility is another concern. Many patients assume that proton therapy is limited to specific locations or that it is out of their financial reach. However, ProCure’s center in Somerset, NJ, is strategically situated to serve residents across the New York and Philadelphia metropolitan areas and beyond. Furthermore, many insurance plans cover this treatment more extensively than patients realize, and ProCure is committed to assisting patients as they navigate the financial implications of their treatment.

The expert team at ProCure, including Dr. Chon and his colleagues, are readily available for interviews and discussions with journalists wishing to deepen public understanding of this vital subject. About ProCure Proton Therapy Center: Situated in Somerset, NJ, this center opened its doors in March 2012, marking the first proton therapy facility in the tri-state area. ProCure treats a spectrum of cancers including prostate, breast, lung, and pediatric cases. Utilizing state-of-the-art radiation treatment, the center has successfully treated over 7,400 patients, demonstrating a commitment to enriching lives through personalized cancer care that often involves fewer side effects and quicker recovery times.

“We aim to empower cancer patients with effective treatment options tailored to their medical needs and lifestyles,” Dr. Chon explains. “Proton therapy not only serves the clinical aspect but also restores a sense of normalcy to patients’ lives, allowing them to cherish what matters most.”

For further exploration, please visit ProCure.com. Interested parties can reach out to Sarah Ferrington, Marketing Manager at ProCure, at 732-357-2609 or via email at [email protected] Media inquiries are encouraged to support broader awareness of this life-changing treatment modality for those battling prostate cancer.